Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TIVC
Upturn stock ratingUpturn stock rating

Tivic Health Systems Inc (TIVC)

Upturn stock ratingUpturn stock rating
$4.15
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: TIVC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$4.15
high$

Analysis of Past Performance

Type Stock
Historic Profit -46.17%
Avg. Invested days 44
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.68M USD
Price to earnings Ratio -
1Y Target Price 210
Price to earnings Ratio -
1Y Target Price 210
Volume (30-day avg) -
Beta 2
52 Weeks Range 2.43 - 16.08
Updated Date 06/29/2025
52 Weeks Range 2.43 - 16.08
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -5.05

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2151.43%

Management Effectiveness

Return on Assets (TTM) -100.63%
Return on Equity (TTM) -218.77%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1673245
Price to Sales(TTM) 7.12
Enterprise Value 1673245
Price to Sales(TTM) 7.12
Enterprise Value to Revenue 3.24
Enterprise Value to EBITDA 0.16
Shares Outstanding 965899
Shares Floating 765790
Shares Outstanding 965899
Shares Floating 765790
Percent Insiders 12.81
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Tivic Health Systems Inc

stock logo

Company Overview

overview logo History and Background

Tivic Health Systems Inc. was founded to develop and commercialize bioelectronic therapies. They focus on non-invasive neuromodulation devices for treating conditions like sinus pain and inflammation. Their primary product is ClearUP.

business area logo Core Business Areas

  • Neuromodulation Devices: Develops and sells non-invasive bioelectronic devices for treating sinus and nasal conditions.

leadership logo Leadership and Structure

The leadership team includes individuals with experience in medical device development and commercialization. The company has a typical organizational structure for a small cap medical device firm, involving R&D, manufacturing, sales, and marketing departments.

Top Products and Market Share

overview logo Key Offerings

  • ClearUP: ClearUP is a non-invasive, over-the-counter device used to relieve sinus pain and congestion. Market share data is difficult to obtain precisely, but it competes with traditional nasal sprays and other sinus relief products. Key competitors include drug manufacturers like Johnson & Johnson (sinus medication).

Market Dynamics

industry overview logo Industry Overview

The market for sinus and nasal relief products is large and competitive, with a mix of pharmaceutical and device-based solutions. The trend towards non-drug therapies is growing.

Positioning

Tivic Health positions itself as a provider of drug-free alternatives for sinus relief, targeting consumers seeking non-pharmaceutical solutions.

Total Addressable Market (TAM)

The TAM for sinus and nasal congestion relief is estimated in billions of dollars annually. Tivic Health is capturing a very small segment of this large market with potential for growth in the non-pharmaceutical sector.

Upturn SWOT Analysis

Strengths

  • Drug-free alternative
  • Non-invasive treatment
  • FDA cleared
  • Over-the-counter availability

Weaknesses

  • Limited market share
  • Relatively new product
  • Requires consumer education
  • Dependence on ClearUP sales

Opportunities

  • Expanding product line
  • Increasing awareness of bioelectronic medicine
  • Partnerships with healthcare providers
  • Geographic expansion

Threats

  • Competition from established pharmaceutical companies
  • Changing consumer preferences
  • Regulatory hurdles
  • Potential for new technologies to emerge

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • AVNS

Competitive Landscape

Tivic Healthu2019s primary advantage is its drug-free, non-invasive approach. Disadvantages include limited market share and brand recognition compared to established pharmaceutical companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is dependent on financial data; Tivic Health is a small cap company with limited history on the public market.

Future Projections: Future growth projections need to be determined based on analyst estimates and the company's strategic plans.

Recent Initiatives: Need to find information on any recent strategic initatives undertaken by the company.

Summary

Tivic Health Systems Inc. offers a novel, drug-free solution for sinus pain, but faces challenges including limited market share and intense competition from established pharmaceutical companies. Expanding its product line, increasing brand awareness, and securing partnerships with healthcare providers are crucial for future growth. Financial stability is important for long-term success, as well as watching the competitors.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tivic Health Systems Inc

Exchange NASDAQ
Headquaters Fremont, CA, United States
IPO Launch date 2021-11-11
Co-Founder, CEO & Director Ms. Jennifer Ernst
Sector Healthcare
Industry Medical Devices
Full time employees 7
Full time employees 7

Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion. The company sells its products through online retailers and commercial distributors, as well as its own website. Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome. In addition, the company markets its commercial product under the ClearUP Sinus Pain Relief brand name. It also focusses on non-invasive vagus nerve stimulation. The company was incorporated in 2016 and is based in Fremont, California.